a 2021

Malignant arrythmic storm, stellate ganglion and diabetes mellitus

JIRAVSKÝ, Otakar, Radim ŠPAČEK, Jan CHOVANČÍK, Radka ŠTĚPÁNOVÁ, Miroslav HUDEC et. al.

Basic information

Original name

Malignant arrythmic storm, stellate ganglion and diabetes mellitus

Authors

JIRAVSKÝ, Otakar (203 Czech Republic, belonging to the institution), Radim ŠPAČEK (203 Czech Republic), Jan CHOVANČÍK (203 Czech Republic), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution), Miroslav HUDEC (203 Czech Republic), Adam SVOBODNÍK (203 Czech Republic, belonging to the institution), Libor ŠKŇOUŘIL (203 Czech Republic) and Martin FIALA (203 Czech Republic)

Edition

EHRA 2021, 2021

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.486

RIV identification code

RIV/00216224:14110/21:00121804

Organization unit

Faculty of Medicine

ISSN

Keywords in English

Malignant arrythmic storm; stellate ganglion; diabetes mellitus

Tags

Tags

International impact, Reviewed
Změněno: 25/2/2022 10:16, Mgr. Tereza Miškechová

Abstract

V originále

Introduction Malignant arrhythmic storm (MAS) increases mortality more than three-fold according to current data. In the acute setting, besides resolving reversible causes, antiarrhythmics are the mainstay of treatment. The role of suppressing the local sympathetic nervous system activity, using stellate ganglion block (SGB) for example, is still being investigated. Purpose To show short-term efficacy of SGB in suppressing the ventricular arrhythmia recurrence in MAS. To identify subgroups of patients with better clinical response after SGB. Methods All consecutive patients with MAS, with standard treatment failure and ventricular arrhythmia recurrence, treated with ultrasound guided SGB, instilating 7ml of 0,5% Bupivacain. 58 MAS treated with SGB durin 2017 – 2020. There were 49 men (84,5%), average age 68,7 +/- 11,4, with average left ventricular EF 28,9 +/- 8,43%. There were 17 diabetics (29,3%). Results When we compare the numbers of defibrillations for sustained ventricular tachycardia 48 hours before and 48 hours after SGB, being the primary therapeutic endpoint in MAS, we see a 96,7% reduction (p < 0,001). When we evaluate ventricular arrhythmias treated with both antitachycardia pacing and shocks, then we see 90% reduction (p < 0,001). The effect of SGB in ventricular arrhythmia suppression was statistically significant during the entire follow-up of 8 days. When we analyzed the cohort, looking for groups showing better response after SGB in terms of ventricular arrhythmia reduction, the only group showing statistical significance in this regard are patients with diabetes mellitus. Conclusions In our cohort, stellate ganglion block is exceptionally effective in the treatment algorithm of malignant arrhythmic storm. SGB shows significantly higher efficacy in the subgroup of patients with diabetes mellitus.

Links

90128, large research infrastructures
Name: CZECRIN III